Cagrilintide stacked with GLP-1s: hype or legit science?

What did @monikavega2 actually say?

She announced she just received a shipment of cagrilintide, which she calls "KAG," and plans to add it to her existing GLP-1 regimen. She noted she has never used it before, that it requires reconstitution, and that she has seen TikToks where people say they "immediately feel it like really strong." She also received another bottle of something called Nabata 100, a separate cosmetic or peptide product that appears to have come bundled with her order. She framed the whole video as a community check-in, asking followers what to expect rather than making specific medical claims. To her credit, she said she wants to start with a small dosage. That is the most responsible thing she said in the entire video.

Does the science back this up?

Cagrilintide is a real investigational compound, but calling it a casual "add-on" to a GLP-1 stack glosses over how little we know about self-administered, compounded versions of it. The clinical data comes from pharmaceutical-grade trials, not vials reconstituted at home.

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. In the SCALE-CAMP trial and subsequent phase 2 work, cagrilintide combined with semaglutide (the combination called CagriSema) produced dose-dependent weight loss, with the highest-dose group losing around 15.6% of body weight at 32 weeks (Enebo et al., 2021, The Lancet). A later phase 3 trial, REDEFINE 1, showed approximately 22.7% weight loss with the fixed-ratio CagriSema combination versus 8.1% with placebo (Wadden et al., 2024, NEJM). Those are meaningful numbers. But every single participant in those trials was monitored closely, used pharmaceutical-grade drug, and had their doses titrated by a clinical team. The compound in that box is not what was used in those trials, and that distinction matters enormously.

What did they get wrong (or right)?

The claim that people "immediately feel it like really strong" is worth questioning. Cagrilintide has a half-life of approximately seven days, which means it is a slow-accumulating drug by design. Acute, immediate effects after a first dose are pharmacologically implausible for a compound with that kind of profile. What people may be feeling is nausea or GI discomfort, which is a known side effect, not a signal that the drug is working well.

She got one thing right: starting with a small dose is sensible. The clinical titration schedules in trials started at 0.16 mg weekly and increased slowly over months for a reason. GI side effects including nausea, vomiting, and diarrhea are common and dose-dependent (Enebo et al., 2021, The Lancet). Stacking an amylin analogue on top of a GLP-1 agonist without medical supervision amplifies that risk considerably. She did not acknowledge that risk at all.

The Nabata 100 product that came bundled in the same package raises separate concerns. Bundling cosmetic or peptide products with a pharmacologically active compound is a red flag about the supply chain she is sourcing from.

What should you actually know?

Cagrilintide is not approved by the FDA as a standalone drug or as part of a compounded product as of 2025. CagriSema as a fixed-ratio combination is in late-stage trials but has not cleared regulatory review. Using compounded cagrilintide means using a product with no guaranteed potency, sterility, or dosing accuracy. Reconstitution errors alone can result in a dose that is 10 times higher or lower than intended.

Combining an amylin analogue with a GLP-1 agonist or dual GIP/GLP-1 agonist like tirzepatide stacks multiple appetite-suppressing and gastric-emptying-slowing mechanisms simultaneously. The additive nausea and cardiovascular effects of that combination have not been studied outside of controlled pharmaceutical trials. Hypoglycemia risk, heart rate changes, and severe GI events are not theoretical concerns here.

• No compounded cagrilintide product has been validated against the pharmaceutical-grade compound used in trials.
• If you are already on tirzepatide, adding a second compound that slows gastric emptying carries real aspiration risk during any medical procedure requiring sedation.
• Ask yourself what the sourcing chain looks like for a vial that arrives in the same box as a "hydro cooling mask."

The bottom line

The trial data on cagrilintide combined with semaglutide is genuinely interesting. The REDEFINE 1 results are among the strongest weight-loss numbers seen in a phase 3 trial. But that science does not transfer automatically to a self-sourced, home-reconstituted vial stacked onto an existing GLP-1 regimen without any clinical oversight. @monikavega2 is asking her followers to validate a decision that carries real pharmacological risk. Enthusiasm is not a substitute for a titration protocol and a prescribing physician.